ArticleNeuro-oncology advances
Relation between tumor treating fields usage rate ≥75% for the first 3 months and progression-free survival in patients with newly diagnosed WHO grade 4 gliomas.
Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Use of tumor treating fields for a malignant brain tumor in a pregnant woman: Case report.Brain & spine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tumor treating fields (TTFields) therapy is an important treatment for glioblastoma. However, there have been few reports showing the effectiveness thereof in clinical settings worldwide. The aim of this study was to examine the efficacy of TTFields therapy by comparing patients with compliance rates above 75% with those below 75% during the first 3 months of treatment. Methods: Data were retrospectively collected from electronic medical records for consecutive patients with newly diagnosed World Health Organization grade 4 gliomas who received TTFields therapy at 12 institutes in Japan from January 2018 to December 2023. Results: In total, 157 patients received TTFields therapy. We analyzed 116 patients who used TTFields for at least the first 3 months. The median age was 57 years; 67 patients were male; and the median KPS before the start of adjuvant temozolomide was 90. The average compliance rate was 78.3%. The median progression-free survival (PFS) and overall survival (OS) were 11.9 months and 23.7 months, respectively. A high compliance rate of TTFields ≥75% for the first 3 months was achieved in 67 patients and was a significant prognostic factor on PFS ( Conclusions: TTFields use rate ≥75% in the first 3 months was significantly associated with improved PFS. There was a tendency for OS to be extended. Further analysis with a larger number of cases is required.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.